IMU completes submission to Hospital Ethics Committees for HER-Vaxx, page-5

Well - this Announcement also tells us a bit more about the trial sites. Clearly Taiwan and Thailand, as well as the Hong Kong Trial. I have posted previously about the Hong Kong site - where the trial will be through the Hong Kong University. From a bit of quick web checking, here is some info about the other two sites.

Novotech says of Taiwan:
Why choose Taiwan for clinical research?

There are many compelling reasons to consider contract research organizations in Taiwan for your clinical research:

• Concentrated patient population
• Fast regulatory and ethical submissions process
• Strong regulatory infrastructure up to ICH level
• GCP-trained clinical professionals fluent in both English and Chinese
• English medical records
• Medical cost is relatively low compared to that in US, Europe and some other Asia countries
• Regular inspections or audits conducted by Taiwan FDA and ECs to ensure quality control.

http://www.novotech-cro.com/locations/taiwan

The Researchers mentioned by Imugene for this trial are Dr Yee Chao and Dr Chia-Jui Yen.

Dr Yee Chao is Professor in Medicine, National Yang-Ming University, Cancer Center, Taipei-Veterans General Hospital, Taiwan. He ran a trial in HER positive gastric cancer for ASLAN Pharma in 2014/15. http://www.biospace.com/News/aslan-pharmaceuticals-pte-ltd-doses-first-patients/345883
Dr Chia-Jui Yen is at the same institution. They were also both involved in a gastric cancer trial for Bristol Myers in 2005. http://ctr.bms.com/pdf//CA139369.pdf

Novotech says of Thailand:
Why choose Thailand for clinical research?

There are many compelling reasons to consider contract research organizations in Thailand for your clinical research:

• Large patient population
• Few competing trials
• Efficient regulatory system
• Highly qualified and educated medical professionals
• Low operational costs
• Well supported IT infrastructure
• High level of GCP compliance
• Efficient trial management and logistics infrastructure.

http://www.novotech-cro.com/locations/thailand

The main researcher mentioned by Imugene for this trial is Dr. Wirote Lausoontornsiri. He was trained in the USA and he is Director of the Center of Excellence for Cancer Treatment and Immunotherapy Research at Sukumvit Hospital (CECTIR) located in Bangkok

Have a great day!
Dave